<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338023</url>
  </required_header>
  <id_info>
    <org_study_id>16036</org_study_id>
    <secondary_id>I4L-GH-ABES</secondary_id>
    <nct_id>NCT03338023</nct_id>
  </id_info>
  <brief_title>A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus®
      in combination with mealtime insulin lispro in adult Chinese participants with Type 1
      Diabetes Mellitus (T1DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change from baseline in HbA1c (LY2963016 noninferior to Lantus®)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c (Lantus® Noninferior to LY2963016)</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change from baseline in HbA1c (Lantus® noninferior to LY2963016)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change from baseline in 7-point SMBG values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c &lt;7%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Percentage of participants with HbA1c &lt;7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c ≤6.5%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Percentage of participants with HbA1c ≤6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability of Fasting Blood Glucose</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Glycemic variability of fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Basal Insulin Dose</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change from baseline in basal insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prandial Insulin Dose</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Prandial insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, 24 Weeks</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Treatment Satisfaction Questionnaire (ITSQ)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>ITSQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Detectable Anti-Glargine Antibodies</measure>
    <time_frame>Baseline through 24 Weeks</time_frame>
    <description>Number of participants with detectable anti-glargine antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Documented Symptomatic Hypoglycemia</measure>
    <time_frame>Baseline through 24 Weeks</time_frame>
    <description>Rate of documented symptomatic hypoglycemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY2963016 + Insulin Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2963016 administered subcutaneously (SC) with insulin lispro administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus® + Insulin Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lantus® administered SC with insulin lispro administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2963016</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY2963016 + Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus®</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Lantus® + Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY2963016 + Insulin Lispro</arm_group_label>
    <arm_group_label>Lantus® + Insulin Lispro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have T1DM based on the disease diagnostic criteria (World Health Organization [WHO]
             Classification).

          -  Have duration of T1DM ≥1 year.

          -  Have HbA1c ≤11 %.

          -  Have been administered with basal-bolus insulins or pre-mixed insulins for at least 90
             days prior to screening.

          -  Have a body mass index (BMI) ≤35 kilograms per meter squared.

        Exclusion Criteria:

          -  Exposure to an insulin glargine other than Lantus® within previous 30 days.

          -  Have had more than one episode of severe hypoglycemia within 6 months prior to entry
             into the study.

          -  Have had more than one episode of diabetic ketoacidosis or emergency room visits for
             uncontrolled diabetes leading to hospitalization within 6 months prior to entry into
             the study.

          -  Have known hypersensitivity or allergy to any of the study insulins (Lantus® or
             insulin lispro) or to excipients of the study insulins.

          -  Are pregnant, intend to become pregnant during the course of the study.

          -  Women who are breastfeeding.

          -  Are currently taking traditional medicine (herbal medicine or patent medicine) with
             known/specified content of anti-hyperglycemic effects within 3 months before
             screening.

          -  Have congestive heart failure Class III and IV.

          -  Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease.

          -  Have any active cancer.

          -  Have a history or diagnosis of human immunodeficiency virus (HIV) infection.

          -  Have presence of clinically significant gastrointestinal disease.

          -  Have a history of renal transplantation, or are currently receiving renal dialysis.

          -  Are receiving chronic systemic glucocorticoid therapy at pharmacological doses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Peoples Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shantou University Medical College No.2 Affiliated Hospital</name>
      <address>
        <city>Shantou</city>
        <state>Guang Dong Province</state>
        <zip>515041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Province People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun-Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital of Henan Science and technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Tongji Hospital</name>
      <address>
        <city>Wu Han</city>
        <state>Hu Bei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changzhou No.2 People's Hospital</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No.2 Hospital Affiliated to Jilin University</name>
      <address>
        <city>Changchun City</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian Med. Univ. No 2 Affiliate Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liao Ning</state>
        <zip>116023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical Universit</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>88798</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Center Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200062</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 15, 2020</verification_date>
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin Glargine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

